Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems.
Bacterial artificial chromosome
Norovirus
Recombinant MVA
Self-excising
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
09 08 2019
09 08 2019
Historique:
received:
05
04
2019
accepted:
05
08
2019
entrez:
11
8
2019
pubmed:
11
8
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Recombinant Modified Vaccinia Virus Ankara has been employed as a safe and potent viral vector vaccine against infectious diseases and cancer. We generated recMVAs encoding norovirus GII.4 genotype capsid protein by using a marker-based approach and a BAC-based system. In the marker-based approach, the capsid gene together with a reporter gene was introduced into the MVA genome in DF-1 cells. Several rounds of plaque purification were carried out to get rid of the WT-MVA. In the BAC-based approach, recMVA-BAC was produced by en passant recombineering in E. coli. Subsequently, the recMVAs were rescued in DF-1 cells using a helper rabbit fibroma virus. The BAC backbone and the helper virus were eliminated by passaging in DF-1 cells. Biochemical characteristics of the recMVAs were studied. We found the purification of the rare spontaneous recombinants time-consuming in the marker-based system. In contrast, the BAC-based system rapidly inserted the gene of interest in E. coli by en passant recombineering before virion production in DF-1 cells. The elimination of the reporter gene was found to be faster and more efficient in the BAC-based approach. With Western blotting and electron microscopy, we could prove successful capsid protein expression and proper virus-assembly, respectively. The MVA-BAC produced higher recombinant virus titers and infected DF-1 cells more efficiently. Comparing both methods, we conclude that, in contrast to the tedious and time-consuming traditional method, the MVA-BAC system allows us to quickly generate high titer recMVAs.
Sections du résumé
BACKGROUND
Recombinant Modified Vaccinia Virus Ankara has been employed as a safe and potent viral vector vaccine against infectious diseases and cancer. We generated recMVAs encoding norovirus GII.4 genotype capsid protein by using a marker-based approach and a BAC-based system. In the marker-based approach, the capsid gene together with a reporter gene was introduced into the MVA genome in DF-1 cells. Several rounds of plaque purification were carried out to get rid of the WT-MVA. In the BAC-based approach, recMVA-BAC was produced by en passant recombineering in E. coli. Subsequently, the recMVAs were rescued in DF-1 cells using a helper rabbit fibroma virus. The BAC backbone and the helper virus were eliminated by passaging in DF-1 cells. Biochemical characteristics of the recMVAs were studied.
RESULTS
We found the purification of the rare spontaneous recombinants time-consuming in the marker-based system. In contrast, the BAC-based system rapidly inserted the gene of interest in E. coli by en passant recombineering before virion production in DF-1 cells. The elimination of the reporter gene was found to be faster and more efficient in the BAC-based approach. With Western blotting and electron microscopy, we could prove successful capsid protein expression and proper virus-assembly, respectively. The MVA-BAC produced higher recombinant virus titers and infected DF-1 cells more efficiently.
CONCLUSIONS
Comparing both methods, we conclude that, in contrast to the tedious and time-consuming traditional method, the MVA-BAC system allows us to quickly generate high titer recMVAs.
Identifiants
pubmed: 31399106
doi: 10.1186/s12985-019-1212-y
pii: 10.1186/s12985-019-1212-y
pmc: PMC6688233
doi:
Substances chimiques
Capsid Proteins
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Références
J Virol. 2002 Apr;76(8):4044-55
pubmed: 11907243
J Virol. 2003 Jul;77(13):7281-90
pubmed: 12805426
Genomics. 2003 Jul;82(1):68-77
pubmed: 12809677
Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71
pubmed: 14529359
Int Microbiol. 2004 Jun;7(2):83-94
pubmed: 15248156
Curr Opin Biotechnol. 2004 Dec;15(6):506-12
pubmed: 15560976
J Biol Chem. 2006 Jul 14;281(28):19478-88
pubmed: 16675449
Lancet. 1991 Mar 9;337(8741):567-72
pubmed: 1671940
J Gen Virol. 2007 Dec;88(Pt 12):3249-59
pubmed: 18024893
J Virol. 2008 Mar;82(6):2975-88
pubmed: 18184713
Clin Vaccine Immunol. 2008 Apr;15(4):691-6
pubmed: 18272665
Vaccine. 2009 Jul 16;27(33):4468-74
pubmed: 19450644
Vaccine. 2009 Oct 23;27(45):6296-9
pubmed: 19840663
Nat Rev Microbiol. 2010 Jan;8(1):62-73
pubmed: 19966816
Vaccine. 2010 Feb 10;28(6):1547-57
pubmed: 19969118
J Gen Virol. 1991 May;72 ( Pt 5):1031-8
pubmed: 2033387
J Virol Methods. 2010 Sep;168(1-2):233-6
pubmed: 20417665
J Virol. 2010 Sep;84(17):8743-52
pubmed: 20538860
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
Comp Immunol Microbiol Infect Dis. 2011 May;34(3):227-36
pubmed: 21146874
J Virol. 2011 Sep;85(17):8656-66
pubmed: 21715504
Methods Mol Biol. 2012;890:59-92
pubmed: 22688761
Nanomedicine (Lond). 2012 Jun;7(6):889-97
pubmed: 22734641
PLoS One. 2012;7(6):e40167
pubmed: 22761956
PLoS One. 2012;7(7):e41625
pubmed: 22844506
J Virol. 2013 Jul;87(13):7282-300
pubmed: 23596307
J Clin Microbiol. 2013 Jul;51(7):2204-11
pubmed: 23637302
J Gen Virol. 2014 Feb;95(Pt 2):278-91
pubmed: 24243731
Methods Mol Biol. 2014;1144:43-62
pubmed: 24671676
Vaccines (Basel). 2014 Jul 29;2(3):624-41
pubmed: 26344749
PLoS One. 2015 Nov 24;10(11):e0143552
pubmed: 26599077
J Virol. 1995 Mar;69(3):1693-8
pubmed: 7853506
Vaccine. 1996 Oct;14(15):1451-8
pubmed: 8994321